Satralizumab: Side Effects, Uses & Monitoring
Facts extracted from current FDA product labeling for Satralizumab. Educational only — not medical advice.
Labeled uses
ENSPRYNG is indicated for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4 (AQP4) antibody positive.
Source: FDA labeling via NIH DailyMed (set 64c156a4…). Not affiliated with FDA or NIH.
Medical disclaimer: Always consult a qualified healthcare professional about any medication.